Skip to main content
EA

Exo Advantage

Exo Advantage supplies clinicians with equipment and treatment protocols that simplify the implementation of regenerative‑medicine therapies, such as concentrated protein supplements and photobiomodulation. Their solutions focus on dose‑optimized, safe, and affordable interventions, and include a workflow platform that streamlines clinical processes while reducing costs. By providing these integrated products, Exo Advantage helps practitioners deliver cutting‑edge, evidence‑based care to patients.

Marshfield, MassachusettsFounded 20245100+ followers
Updated 1 month ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Clinicians often lack affordable, FDA‑compliant equipment and standardized protocols for delivering regenerative therapies such as photobiomodulation, concentrated protein supplements, exosomes, and cellular aspirates, making it difficult to provide consistent, high‑dose treatments to all patients.

Solution

Exo Advantage offers a unified platform of FDA 510(k) and MDSAP‑compliant devices and dosing protocols that simplify the implementation of regenerative medicine procedures. The product line includes photobiomodulation units and systems for delivering concentrated protein and growth‑factor supplements, each paired with clear, evidence‑based dosing guidance. By integrating these tools on a common workflow, the platform reduces procedural complexity and improves reproducibility across different tissue sources. The company guarantees lower pricing and transparent costs, enabling clinics to offer advanced regenerative treatments without prohibitive expense.

Target Audience

Primary customers are regenerative medicine clinics, orthopedic and sports medicine practices, and aesthetic providers seeking FDA‑compliant, cost‑effective equipment and protocols for advanced cellular and protein‑based therapies.

Features

  • FDA 510(k) and MDSAP‑approved photobiomodulation device for mitochondrial repair and high‑dose therapy
  • Concentrated protein and exosome delivery system with standardized dosing protocols
  • Integrated platform that unifies equipment, protocols, and dose calculations for streamlined workflow
  • Compatibility with multiple regenerative tissue sources, including bone marrow aspirate and adipose aspirate
  • Pricing model that ensures guaranteed lower costs and pricing transparency for providers
This profile is AI-generated and may contain inaccuracies.